Correction: Cliniclal benefit of 1-year certolizumab pegol(CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritiswas observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Translational Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768112/
http://dx.doi.org/10.1136/annrheumdis-2016-210246corr1
_version_ 1784854094822768640
collection PubMed
description
format Online
Article
Text
id pubmed-9768112
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-97681122022-12-21 Correction: Cliniclal benefit of 1-year certolizumab pegol(CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritiswas observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial Ann Rheum Dis Translational Science BMJ Publishing Group 2022-09 2022-08-10 /pmc/articles/PMC9768112/ http://dx.doi.org/10.1136/annrheumdis-2016-210246corr1 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Translational Science
Correction: Cliniclal benefit of 1-year certolizumab pegol(CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritiswas observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial
title Correction: Cliniclal benefit of 1-year certolizumab pegol(CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritiswas observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial
title_full Correction: Cliniclal benefit of 1-year certolizumab pegol(CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritiswas observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial
title_fullStr Correction: Cliniclal benefit of 1-year certolizumab pegol(CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritiswas observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial
title_full_unstemmed Correction: Cliniclal benefit of 1-year certolizumab pegol(CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritiswas observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial
title_short Correction: Cliniclal benefit of 1-year certolizumab pegol(CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritiswas observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial
title_sort correction: cliniclal benefit of 1-year certolizumab pegol(czp) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritiswas observed following czp discontinuation: 2-year results of the c-opera study, a phase iii randomised trial
topic Translational Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768112/
http://dx.doi.org/10.1136/annrheumdis-2016-210246corr1

Ejemplares similares